Martin Holst Lange
Martin Holst Lange is the head of development at Novo Nordisk, a global healthcare company known for its innovations in diabetes and obesity treatments. Recently, he announced that the company will explore the potential of its GLP-1 obesity drugs to assist patients struggling with addiction, emphasizing the need for rigorous scientific and regulatory investigation into this promising area.
Not in the pool (under ¢1).
Recent news mentions
Martin Holst Lange, the Novo Nordisk chief scientific officer, said based on the 'significant unmet need', the company felt it 'had a responsibility to explore semaglutide’s potential, despite a low likelihood of success'.
Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials | Pharmaceuticals industry
United Kingdom· 2025-11-25
Martin Holst Lange is the research chief at Novo Nordisk who commented on the expected approval for oral weight loss medication.
Novo præsenterer nye lovende data for Wegovy-pille
Denmark· 2025-09-17Martin Holst Lange, the head of research and development at Novo Nordisk, stated that they want to gather evidence on the effects of drugs for common ailments affecting patients' daily lives.
Novo Nordisk po revoluciji v hujšanju želi razviti zdravila za nespečnost
Slovenia· 2025-09-17Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.
Experimental drug helps people lose nearly 25% of body weight
United States· 2025-06-29
Martin Holst Lange, head of development at Novo Nordisk, discussed exploring how obesity drugs can help patients with addiction.
Novo Nordisk to explore how obesity drugs can help patients with addiction – The Irish Times
Ireland· 2025-03-06